A Phase 2 interventional study of Sub-retinal transplantation of MA09-hRPE cells and tacrolimus and mycophenolate mofetil in Age-Related Macular Degeneration, sponsored by Astellas Institute for Regenerative Medicine. Withdrawn at 1 site in United States. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2017-07-26.
Sponsored by Astellas Institute for Regenerative Medicine (part of Astellas Pharma Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Macular Degeneration by Astellas Pharma Inc — 3 open to participants now, 5 under way, none of them phase 3. Macular Degeneration · Astellas Pharma Inc.
Among the 23 studies in Macular Degeneration by Astellas Pharma Inc, this one is the 19th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2015, is one of 6 in phase 2, and was the 13th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →3 of the 23 studies in Macular Degeneration by Astellas Pharma Inc are open now, in 1 country. Recruiting first, the newest first:
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 6+
Astellas Pharma Global Development, Inc. · Sites in United States
Ages 6+
Astellas Institute for Regenerative Medicine · Sites in United States
Ages 50+
By country, each count listing its studies:
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 5 · Phase 4 1
First in 2007; this study’s year is marked. 1 started in 2015.
By drug class, each counting the studies that test any of its medicines:
Median enrollment 63 across the 19 interventional studies, 51 across the 4 observational. Of the 17 that completed or were terminated, 10 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Astellas Institute for Regenerative Medicine, one of the names counted as Astellas Pharma Inc. Under that name alone:
Astellas Institute for Regenerative Medicine is the lead sponsor of 10 studies on the registry; 3 are open to participants now.
1 of the studies in Macular Degeneration by Astellas Pharma Inc that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06970665Astellas Pharma IncA Study About the Safety of ASP3021 Eye Injections and if They Help People in Japan With Vision Loss From Age-related Macular Degeneration | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 23 studies in Macular Degeneration by Astellas Pharma Inc, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety of 3 regimens of short-term, low-dose systemic IMT as rejection prophylaxis prior to and/or following transplant of MA09-hRPE cells.
This study will be a Phase 2, double-masked, randomized, parallel group, sham surgery/placebo control, multi-center trial. Subjects will be randomized in a 3:1 ratio to either the treatment or control group respectively. Subjects randomized to the treatment group will receive transplantation with 200,000 MA09-hRPE (human embryonic stem cell derived retinal pigmented epithelial)cells in one eye. Subjects randomized to the control group will have a sham surgery without transplantation of MA09-hRPE cells. The study eye must meet all eligibility criteria. If both eyes meet all eligibility criteria, then the study eye will be the eye with the worst Best Corrected Visual Acuity (BCVA) score at screening. If both eyes have identical BCVA scores, then the study eye will be chosen by the Investigator and the subject. There will be 3 cohorts, each with a different regimen of low-dose IMT [tacrolimus and mycophenolate mofetil (MMF)]. Subjects will be randomized to treatment or control within cohorts, defined by severity of BCVA in the study eye at Screening. Enrollment in Cohort 1 and 2 will be concurrent. Enrollment into Cohort 3 will begin once Cohort 2 is fully enrolled.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Sham surgery and placebo immunosuppressive therapy (IMT)
Drug: Placebo tacrolimus and mycophenolate mofetil · Procedure: Sham Surgery
Sub-retinal transplantation of MA09-hRPE cells and IMT
Biological: Sub-retinal transplantation of MA09-hRPE cells · Drug: tacrolimus and mycophenolate mofetil
transplantation
Drug pages: Tacrolimus · Mycophenolic Acid
Immunosuppressive Agents
placebo
Sham surgery
Number of subjects with evidence of graft failure or rejection.
Time frame: 18 months
Change in area of geographic atrophy by Optical coherence tomography
Change from baseline to Week 78
Time frame: 18 months
Change in area of geographic atrophy by Autofluorescence
Change from baseline to Week 78
Time frame: 18 months
Change in average Best Corrected Visual Acuity (BCVA)
Change from baseline to Week 78
Time frame: 18 months
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Aug 2015 to primary completion in May 2017, 20 months.
How these figures are worked out, and which studies are left out of them.
This study is withdrawn, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Tacrolimus · Mycophenolic Acid
Astellas Institute for Regenerative Medicine →